Comparable stake leader
CVI Investments, Inc.
SEC ownership of Citius Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001506251.
Disclosed value leader
CVI Investments, Inc.
Comparable rows
44/50
Latest evidence
30 Jun 2026
- Public ticker
- CTXR on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
CVI Investments, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
44 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
CVI Investments, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001506251
- Issuer location
- Cranford, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Citius Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CVI Investments, Inc.
Disclosed value leader
CVI Investments, Inc.
Comparable rows
44/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
6 rows are not safely comparable across share classes.
13D/G row: CVI Investments, Inc.
Showing 1-8 of 50 holder rows.
Quick read
CVI Investments, Inc. leads the comparable SEC ownership view at 9.9%.
44 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CVI Investments, Inc.'s linked filing trail.
Comparable ownership
Top 5
CVI Investments, Inc.
9.9%
GEODE CAPITAL MANAGEMENT, LLC
0.71%
VANGUARD CAPITAL MANAGEMENT LLC
0.65%
Miller Financial Services LLC
0.43%
CITADEL ADVISORS LLC
0.41%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
9.9%
|
$1,624,606
3,008,529 shares
|
+$331,454 | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.71%
|
$130,302
215,537 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
0.65%
|
$119,405
197,364 shares
|
— | 30 Jun 2026 |
| Miller Financial Services LLC |
13F
Company
|
0.43%
|
$78,585
130,000 shares
|
— | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.41%
|
$75,508
124,910 shares
|
— | 30 Jun 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
0.4%
|
$74,255
122,837 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
0.26%
|
$47,042
77,755 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
0.23%
|
$42,224
69,850 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 17 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to Citius Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
Leonard L. Mazur
Net 12M change
$0
Latest report
08 Aug 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Leonard L. Mazur | Chief Executive Officer, Director | $574,299 | Mixed | 08 Aug 2025 | ||
| Myron Z. Holubiak | Vice Chairman, Director | $124,316 | Mixed | 08 Aug 2025 | ||
| Jaime Bartushak | Chief Financial Officer | $45,265 | Mixed | 07 Nov 2024 | ||
| Carol Webb | Director | $8,876 | Mixed | 07 Nov 2024 | ||
| Eugene Myron Holuka | Director | $1,775 | Mixed | 07 Nov 2024 | ||
| Howard Safir | Director | Mixed | 04 Oct 2022 | |||
| Suren G. Dutia | Director | Mixed | 07 Nov 2024 | |||
| Dennis M. Mcgrath | Director | Mixed | 07 Nov 2024 | |||
| William Kane | Director | Mixed | 04 Oct 2022 | |||
| Robert Joseph Smith | Director | Mixed | 07 Nov 2024 | |||
| Myron Czuczman | Chief Medical Officer | Mixed | 07 Nov 2024 |
Recent insider transactions for Citius Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.